90060-42-7
90060-42-7
Chemical Structure
Nolomirole
Synonym(s): CHF 1035 free base
- CAS No.: 90060-42-7
- Formula:C19H27NO4
- Molecular Weight:333.42
IUPAC Name: 6-(methylamino)-5,6,7,8-tetrahydronaphthalene-1,2-diyl bis(2-methylpropanoate)
InChIKey: OMMYLOLVPCCZQZ-UHFFFAOYSA-N
SMILES: CC(C)C(OC1=C2C(CC(NC)CC2)=CC=C1OC(C(C)C)=O)=O
Biological Activity: Nolomirole (CHF 1035) is an orally active and selective DA2 dopaminergic receptor/α2-adrenoceptor agonist. Nolomirole attenuates the heart failure signs in the Monocrotaline (HY-N0750)-induced congestive heart failure model. Nolomirole increases cardiac output[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Nolomirole | Nolomirole (CHF 1035) is an orally active and selective DA2 dopaminergic receptor/α2-adrenoceptor agonist. Nolomirole attenuates the heart failure signs in the Monocrotaline (HY-N0750)-induced congestive heart failure model. Nolomirole increases cardiac output. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. 1. Afzal M. Recent updates on novel therapeutic targets of cardiovascular diseases. Mol Cell Biochem. 2021 Jan; 476(1):145-155. [Content Brief]
- [2]. 2. Torp-Pedersen C, et al. A randomised trial of a pre-synaptic stimulator of DA2-dopaminergic and alpha2-adrenergic receptors on morbidity and mortality in patients with heart failure. Eur J Heart Fail. 2008 Jan; 10(1):89-95. [Content Brief]
- [3]. 3. Tjeerdsma G, et al. Autonomic and hemodynamic effects of a new selective dopamine agonist, CHF1035, in patients with chronic heart failure. Cardiovasc Drugs Ther. 2001 Mar; 15(2):139-45. [Content Brief]
- [4]. 4. Pasini E, et al. Effect of nolomirole on monocrotaline-induced heart failure. Pharmacol Res. 2004 Jan; 49(1):1-5. [Content Brief]
